Use of metformin, empagliflozin, and their combination showed significant improvement in TNF‐α levels (PCOS‐IR Met, 76.21 ± 8.47; PCOS‐IR Empa, 76.02 ± 6.17; PCOS‐IR Met+Empa, 50.41 ± 7.07 vs. PCOS‐IR 133.84 ± 31.5 p < 0.05), and IL6 levels (PCOS‐IR Met, 70.36 ± 5.86; PCOS‐IR Empa, 68.78 ± 8.44; PCOS‐IR Met+Empa, 46.64 ± 4.85 vs. PCOS‐IR 127.21 ± 5.63 p < 0.05). Here, IL6 is linked to polycystic ovary syndrome.